Thai national guidelines for the use of antiretroviral therapy in pediatric HIV infection in 2010

1. WHO antiretroviral therapy for infants and children 2008; April 2008. http://www.who.int/hiv/pub/paediatric/WHO_Paediatric_ART_guideline_rev_mreport_2008.pdf; Access November 24, 2009.Search in Google Scholar

2. PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection. http://www.pentatrials.org/guide09.pdf; Accessed 31 July, 2009.Search in Google Scholar

3. Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. February 23, 2009. http://aidsinfo.nih.gov/ContentFiles/PediatricGuidelines.pdf; Access 24 November, 2009.Search in Google Scholar

4. Schneider E, Whitmore S, Glynn KM, Dominguez K, Mitsch A, McKenna MT. Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged <18 months and for HIV infection and AIDS among children aged 18 months to <13 years - United States, 2008. MMWR Recomm Rep. 2008; 57:1-12.Search in Google Scholar

5. Violari A, Cotton MF, Gibb DM, Babiker AG, Steyn J, Madhi SA, et al. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med. 2008; 359:2233-44.10.1056/NEJMoa0800971295002119020325Search in Google Scholar

6. Lapphra K, Vanprapar N, Chearskul S, Phongsamart W, Chearskul P, Prasitsuebsai W, et al. Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children. Int J Infect Dis. 2008;12:e33-8.10.1016/j.ijid.2007.10.00818573672Search in Google Scholar

7. Puthanakit T, Aurpibul L, Oberdorfer P, Akarathum N, Kanjanavanit S, Wannarit P, et al. Sustained immunologic and virologic efficacy after four years of highly active antiretroviral therapy in human immunodeficiency virus infected children in Thailand. Pediatr Infect Dis J. 2007; 26:953-6.10.1097/INF.0b013e318125720a17901804Open DOISearch in Google Scholar

8. Eshleman SH, Hoover DR, Hudelson SE, Chen S, Fiscus SA, Piwowar-Manning E, et al. Development of nevirapine resistance in infants is reduced by use of infant-only single-dose nevirapine plus zidovudine postexposure prophylaxis for the prevention of mother-to-child transmission of HIV-1. J Infect Dis. 2006; 193:479-81.10.1086/49996716425125Search in Google Scholar

9. Chalermchockcharoenkit A, Culnane M, Chotpitayasunondh T, Vanprapa N, Leelawiwat W, Mock PA, et al. Antiretroviral resistance patterns and HIV-1 subtype in mother-infant pairs after the administration of combination short-course zidovudine plus single-dose nevirapine for the prevention of mother-to-child transmission of HIV. Clin Infect Dis. 2009; 49:299-305.10.1086/59961219522656Search in Google Scholar

10. Palumbo P, Violari A, Lindsey J, Hughes M, Jean-Philippe P, Mofenson L, et al. Nevirapine (NVP) vs lopinavir-ritonavir (LPV/r)-based antiretroviral therapy (ART) in single dose nevirapine (sdNVP)-exposed HIV-infected infants: preliminary results from the IMPAACT P1060 trial. Presented at 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town, South Africa, 19-22 July 2009 (Abstract LBPEB12).Search in Google Scholar

11. Puthanakit T, Oberdorfer P, Akarathum N, Wannarit P, Sirisanthana T, Sirisanthana V. Immune reconstitution syndrome after highly active antiretroviral therapy in human immunodeficiency virus-infected thai children. Pediatr Infect Dis J. 2006; 25:53-8.10.1097/01.inf.0000195618.55453.9a192453016395104Search in Google Scholar

12. Manosuthi W, Mankatitham W, Lueangniyomkul A, Chimsuntorn S, Sungkanuparph S. Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin. HIV Med. 2008; 9: 294-9.10.1111/j.1468-1293.2008.00563.x18400076Search in Google Scholar

13. Manosuthi W, Sungkanuparph S, Thakkinstian A, Rattanasiri S, Chaovavanich A, Prasithsirikul W, et al. Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin. Clin Infect Dis. 2006; 43:253-5.10.1086/50521016779754Open DOISearch in Google Scholar

14. Puthanakit T, Jourdain G, Hongsiriwon S, Suntarattiwong P, Chokephaibulkit K, Sirisanthana V, et al. HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. HIV Med. 2010 Mar 25. [Epub ahead of print].10.1111/j.1468-1293.2010.00828.x20345882Search in Google Scholar

15. Ramos JT, De José MI, Dueñas J, Fortuny C, González-Montero R, Mellado MJ, et al. Safety and antiviral response at 12 months of lopinavir/ritonavir therapy in human immunodeficiency virus-1-infected children experienced with three classes of antiretrovirals. Pediatr Infect Dis J. 2005; 24:867-73.10.1097/01.inf.0000180574.18804.9016220083Search in Google Scholar

16. Macassa E, Delaugerre C, Teglas JP, Jullien V, Tréluyer JM, Veber F, et al. Change to a once-daily combination including boosted atazanavir in HIV-1- infected children. Pediatr Infect Dis J. 2006; 25:809-14.10.1097/01.inf.0000234069.37972.9416940839Search in Google Scholar

17. Bunupuradah T, van der Lugt J, Kosalaraksa P, Engchanil C, Boonrak P, Puthanakit T, et al. Safety and efficacy of a double-boosted protease inhibitor combination, saquinavir and lopinavir/ritonavir, in pretreated children at 96 weeks. Antivir Ther. 2009; 14: 241-8.10.1177/135965350901400218Search in Google Scholar

18. Plipat N, Cressey TR, Vanprapar N, Chokephaibulkit K. Efficacy and plasma concentrations of indinavir when boosted with ritonavir in human immunodeficiency virus-infected Thai children. Pediatr Infect Dis J. 2007; 26:86-8.10.1097/01.inf.0000247140.94669.1b17195716Search in Google Scholar

19. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, et al. Update of the drug resistance mutations in HIV-1. Top HIV Med. 2008; 16:138-45.Search in Google Scholar

20. Sohn AH, Ananworanich J. Highly active antiretroviral therapy for children with treatment failure. HIV Therapy. 2009; 3:485-99.10.2217/hiv.09.28Search in Google Scholar